Medroxyprogesterone

DRUG INFORMATION

  ADULT
    - The recommended dose is 150 mg of medroxyprogesterone acetate injectable
      suspension every 3 months (13 weeks) administered by deep, intramuscular (IM)
      injection in the gluteal or deltoid muscle.
      Source: US FDA label for medroxyprogesterone (medroxyprogesterone acetate),
      section 'dosage and administration', retrieved 2026-08-29
    - (2.1) 2.1 Prevention of Pregnancy Both the 1 mL vial and the 1 mL prefilled
      syringe of medroxyprogesterone acetate injectable suspension should be vigorously
      shaken just before use to ensure that the dose being administered represents a
      uniform suspension.
      Source: US FDA label for medroxyprogesterone (medroxyprogesterone acetate),
      section 'dosage and administration', retrieved 2026-08-29
    - The recommended dose is 150 mg of medroxyprogesterone acetate injectable
      suspension every 3 months (13 weeks) administered by deep intramuscular (IM)
      injection using strict aseptic technique in the gluteal or deltoid muscle,
      rotating the sites with every injection.
      Source: US FDA label for medroxyprogesterone (medroxyprogesterone acetate),
      section 'dosage and administration', retrieved 2026-08-29

  CHILD
    - Medroxyprogesterone acetate is not indicated before menarche. Use of
      medroxyprogesterone acetate is associated with significant loss of BMD. This loss
      of BMD is of particular concern during adolescence and early adulthood, a critical
      period of bone accretion. In adolescents, interpretation of BMD results should
      take into account patient age and skeletal maturity.
      Source: US FDA label for medroxyprogesterone (medroxyprogesterone acetate),
      section 'pediatric use', retrieved 2026-08-29

  RENAL IMPAIRMENT
    - No kidney-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for medroxyprogesterone
      (medroxyprogesterone acetate), retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - No liver-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for medroxyprogesterone
      (medroxyprogesterone acetate), retrieved 2026-08-29

  PREGNANCY
    - Risk Summary There is no use for contraception in pregnancy; therefore,
      medroxyprogesterone acetate should be discontinued during pregnancy.
      Source: US FDA label for medroxyprogesterone (medroxyprogesterone acetate),
      section 'pregnancy', retrieved 2026-08-29
    - Epidemiologic studies and meta-analyses have not found an increased risk of
      genital or non-genital birth defects (including cardiac anomalies and limb-
      reduction defects) following exposure to progestins before conception or during
      early pregnancy.
      Source: US FDA label for medroxyprogesterone (medroxyprogesterone acetate),
      section 'pregnancy', retrieved 2026-08-29
    - All pregnancies have a background risk of birth defect, loss, or other adverse
      outcomes.
      Source: US FDA label for medroxyprogesterone (medroxyprogesterone acetate),
      section 'pregnancy', retrieved 2026-08-29

  BREASTFEEDING
    - Medroxyprogesterone acetate is indicated for the prevention of pregnancy and would
      therefore be expected to impair female fertility until cessation of treatment.
      Source: US FDA label for medroxyprogesterone (medroxyprogesterone acetate),
      section 'nursing mothers', retrieved 2026-08-29
    - Women may experience a delay in return to ovulation and fertility (conception)
      following discontinuation of medroxyprogesterone acetate [see Warnings and
      Precautions ( 5.15 ) ] .
      Source: US FDA label for medroxyprogesterone (medroxyprogesterone acetate),
      section 'nursing mothers', retrieved 2026-08-29
    - ( 8.1 ) Lactation: Detectable amounts of drug have been identified in the milk of
      mothers receiving medroxyprogesterone acetate.
      Source: US FDA label for medroxyprogesterone (medroxyprogesterone acetate),
      section 'use in specific populations', retrieved 2026-08-29